- Home
- CRT vs TVRD Comparison
CRT vs TVRD Comparison
Compare CRT & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CRT | TVRD |
|---|---|---|
| Founded | 1991 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.5M | 34.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CRT | TVRD |
|---|---|---|
| Price | $9.01 | $4.00 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $51.67 |
| AVG Volume (30 Days) | 29.7K | ★ 49.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 7.59% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.55 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.07 | $3.50 |
| 52 Week High | $13.31 | $43.65 |
Technical Indicators
Market Signals| Indicator | CRT | TVRD |
|---|---|---|
| Relative Strength Index (RSI) | 64.92 | 53.32 |
| Support Level | $8.38 | $3.81 |
| Resistance Level | $9.17 | $4.45 |
| Average True Range (ATR) | 0.20 | 0.25 |
| MACD | 0.03 | 0.06 |
| Stochastic Oscillator | 81.87 | 78.67 |
Price Performance
Historical ComparisonAbout CRT Cross Timbers Royalty Trust
Cross Timbers Royalty Trust is a United States-based trust. The net profits interests are derived from producing royalty, overriding royalty interests, and working interest properties. The underlying properties of the trust include producing properties in Texas, Oklahoma, and New Mexico.
About TVRD Tvardi Therapeutics Inc.
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.